Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NRAS Q61L |
| Therapy | AZD5991 + Selumetinib |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NRAS Q61L | acute myeloid leukemia | sensitive | AZD5991 + Selumetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Koselugo (selumetinib) and AZD5991 synergistically inhibited viability of an acute myeloid leukemia cell line harboring NRAS Q61L in culture (PMID: 38456804). | 38456804 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38456804) | Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations. | Full reference... |